No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in
Seung-Gul Kang1, Jung-Eun Choi, Hyonggin An
1Department of Psychiatry, Korea University College of Medicine, and Kangbuk Samsung Hospital, Seoul, South Korea.
Objective:
This study investigated whether the brain-derived neurotrophic factor (BDNF) gene Val66Met single-nucleotide polymorphism (SNP) is associated with antipsychotic-induced tardive dyskinesia (TD) in schizophrenia.
Methods:
Genotyping was performed for the BDNF gene Val66Met SNP in Korean schizophrenic patients with (n=83) and without TD (n=126) who were matched for antipsychotic drug exposure and other relevant variables.
Results:
The frequencies of genotypes (chi2=2.37, p=0.306) and alleles (chi2=0.03, p=0.867) did not differ significantly between these two groups.
Conclusion:
These findings suggest that the BDNF polymorphism does not play a major role in the susceptibility to TD in schizophrenic patients.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.


